{"chunk_id": "medquad__chunk_47960", "source": "medquad", "text": "e GH receptor antagonists (GHRAs), which interfere with the action of GH. They normalize IGF-I levels in more than 90 percent of patients. They do not, however, lower GH levels. Given once a day through injection, GHRAs are usually well-tolerated by patients. The long-term effects of these drugs on tumor growth are still under study. Side effects can include headaches, fatigue, and abnormal liver function.\n                \nDopamine agonists make up the third medication group. These drugs are not"}